Login to Your Account

Amgen Hits Endpoints In First Enbrel Psoriasis Phase III Trial

By Brady Huggett

Tuesday, January 21, 2003
The first of two Enbrel Phase III trials in psoriasis hit its primary and secondary endpoints, pushing Amgen Inc. to the halfway point in its quest to grow the blockbuster drug through the addition of another large market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription